Geskovski Nikola, Matevska-Geshkovska Nadica, Dimchevska Sazdovska Simona, Glavas Dodov Marija, Mladenovska Kristina, Goracinova Katerina
Institute of Pharmaceutical Technology, Faculty of Pharmacy, University of Ss. Cyril and Methodius in Skopje, Skopje, North Macedonia.
Center for Pharmaceutical Biomolecular Analyses, Faculty of Pharmacy, University of Ss. Cyril and Methodius in Skopje, Skopje, North Macedonia.
Beilstein J Nanotechnol. 2021 Apr 29;12:375-401. doi: 10.3762/bjnano.12.31. eCollection 2021.
Nanomedicine has emerged as a novel cancer treatment and diagnostic modality, whose design constantly evolves towards increasing the safety and efficacy of the chemotherapeutic and diagnostic protocols. Molecular diagnostics, which create a great amount of data related to the unique molecular signatures of each tumor subtype, have emerged as an important tool for detailed profiling of tumors. They provide an opportunity to develop targeting agents for early detection and diagnosis, and to select the most effective combinatorial treatment options. Alongside, the design of the nanoscale carriers needs to cope with novel trends of molecular screening. Also, multiple targeting ligands needed for robust and specific interactions with the targeted cell populations have to be introduced, which should result in substantial improvements in safety and efficacy of the cancer treatment. This article will focus on novel design strategies for nanoscale drug delivery systems, based on the unique molecular signatures of myeloid leukemia and EGFR/CD44-positive solid tumors, and the impact of novel discoveries in molecular tumor profiles on future chemotherapeutic protocols.
纳米医学已成为一种新型的癌症治疗和诊断方式，其设计不断朝着提高化疗和诊断方案的安全性和有效性发展。分子诊断能够生成大量与每种肿瘤亚型独特分子特征相关的数据，已成为肿瘤详细剖析的重要工具。它们为开发用于早期检测和诊断的靶向药物以及选择最有效的联合治疗方案提供了契机。与此同时，纳米级载体的设计需要应对分子筛查的新趋势。此外，还必须引入与靶向细胞群体进行稳固且特异性相互作用所需的多种靶向配体，这有望大幅提高癌症治疗的安全性和有效性。本文将聚焦基于髓系白血病和EGFR/CD44阳性实体瘤的独特分子特征的纳米级药物递送系统的新型设计策略，以及分子肿瘤图谱中的新发现对未来化疗方案的影响。
